Trastuzumab deruxtecan (T-DXd) significantly improves IDFS over trastuzumab emtansine (T-DM1) in high-risk HER2-positive early breast cancer post-neoadjuvant therapy. The DESTINY-Breast05 trial ...
(Sharecast News) - London stocks nudged lower in early trade on Tuesday as investors considered the implications of a potential US government shutdown and digested the latest UK GDP data. At 0845 BST, ...
Deutsche Bank analysts say that one bubble in artificial intelligence may have already deflated — and that is the rush to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback